TITLE

Single-Dose Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis in India: A Multicenter Study

AUTHOR(S)
Sundar, S.; Jha, T.K.; Thakur, C.P.; Mishra, M.; Singh, V.P.; Buffels, R.
PUB. DATE
September 2003
SOURCE
Clinical Infectious Diseases;9/15/2003, Vol. 37 Issue 6, p800
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents a multicenter study of single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India. Safety profile of the drug; Percentage of cure of the drug; Impact of widespread antimony resistance on the use of amphotericin B; Adverse events seen.
ACCESSION #
10869098

 

Related Articles

  • Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic... Berman, J.D.; Badaro, R.; Thakur, C.P.; Wasunna, K.M.; Behbehani, K.; Davidson, R.; Kuzoe, F.; Pang, L.; Weerasuriya, K.; Bryceson, A.D.M. // Bulletin of the World Health Organization;1998, Vol. 76 Issue 1, p25 

    Studies the efficacy and safety of liposomal amphotericin B (AmBisome) for treating visceral leishmaniasis (kala-azar) in Brazil, Kenya and India where the disease is endemic. Details on the treatment of 10 patients with AmBisome; Methodology used to conduct the study; Findings of the study.

  • Visceral Leishmaniasis during Childhood in Southern Greece. Maltezou, H.C.; Siafas, C.; Mavrikou, M.; Spyridis, P.; Stavrinadis, C.; Karpathios, Th.; Kafetzis, D. A. // Clinical Infectious Diseases;11/1/2000, Vol. 31 Issue 5, p1139 

    Presents a study of immunocompetent children from southern Greece who were diagnosed with visceral leishmaniasis. Information on visceral leishmaniasis; Evaluation of access to medical services by the patient; Obstacle to the use of liposomal amphotericin B.

  • Immune haemolytic anaemia due to visceral leishmaniasis in a young child: Reply. Dotis, John; Roilides, Emmanuel // European Journal of Pediatrics;2003, Vol. 162 Issue 6, p445 

    Presents the views of the authors on the incidence of immune haemolytic anemia due to visceral leishmaniasis. Need of an urgent and low-cost approach to the treatment of leishmaniasis; Use of the immunochromatographic dipstick test for the diagnosis of leishmaniasis; Difficulties in the use of...

  • Correction: Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India.  // PLoS Neglected Tropical Diseases;Apr2014, Vol. 8 Issue 4, p1 

    A correction to the article "Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India" that was published in the 2014 issue is presented.

  • Antileishmanial activity of nano-amphotericin B deoxycholate. Krishna Das Manandhar; Thakur Prasad Yadav; Vijay Kumar Prajapati; Subodh Kumar; Madhukar Rai; Anuradha Dube; Onkar Nath Srivastava; Shyam Sundar // Journal of Antimicrobial Chemotherapy (JAC);Aug2008, Vol. 62 Issue 2, p376 

    Objectives The aim of the present study was to compare the efficacy of a nano form of amphotericin B deoxycholate with that of conventional amphotericin B deoxycholate for the treatment of visceral leishmaniasis. Methods We have formulated nanoparticles (10–20 nM) from amphotericin...

  • Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Chappuis, François; Sundar, Shyam; Hailu, Asrat; Ghalib, Hashim; Rijal, Suman; Peeling, Rosanna W.; Alvar, Jorge; Boelaert, Marleen // Nature Reviews Microbiology;Nov2007, Vol. 5 Issue 11, p873 

    Visceral leishmaniasis (VL) is a systemic protozoan disease that is transmitted by phlebotomine sandflies. Poor and neglected populations in East Africa and the Indian sub-continent are particularly affected. Early and accurate diagnosis and treatment remain key components of VL control. In...

  • Investments in Research and Surveillance Are Needed to Go Beyond Elimination and Stop Transmission of Leishmania in the Indian Subcontinent. Olliaro, Piero L.; Shamsuzzaman, Tushar A. K. M.; Marasini, Baburam; Dhariwal, A. C.; Be-Nazir, Ahmed; Mondal, Dinesh; Banjara, Megha Raj; Das, Pradeep; Sundar, Shyam; Rijal, Suman; Arana, Byron; Alvar, Jorge; Argaw, Daniel; Peeling, Rosanna W.; Kroeger, Axel; Matlashewski, Greg // PLoS Neglected Tropical Diseases;1/26/2017, Vol. 11 Issue 1, p1 

    The article offers information on the Kala-azar Elimination Programme focusing to eliminate visceral leishmaniasis as a public health problem. It mentions improved treatments for visceral leishmaniasis offered through liposomal amphotericin B, paromomycin, and miltefosine. It also mentions that...

  • Visceral leishmaniasis in a patient with Down syndrome. Colomba, Claudia; Saporito, Laura; Giordano, Salvatore; Infurnari, Laura; Ajovalasit, Patrizia; Titone, Lucina // European Journal of Pediatrics;Feb2006, Vol. 165 Issue 2, p140 

    The article focuses on a case of visceral leishmaniasis that occurred in a child with a cardiopathic condition and Down syndrome. After undergoing a surgical intervention for congenital cardiopathy, a 6-month-old child with Down syndrome returned to paediatric cardiosurgery department with...

  • Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India. Thakur, C. P.; Kumar, Amit; Mitra, Gaurab; Thakur, Shabnam; Sinha, P. K.; Das, P.; Bhattacharya, S. K.; Sinha, Arun // Indian Journal of Medical Research;Jul2008, Vol. 128 Issue 1, p38 

    Background & objectives: Of the two reservoirs of infection of kala-azar Le., patients of kala-azar and post kala-azar dermal leishmaniasis (PKDL), PKDL provides easy access for the sandfly to pick up the parasites. In the last epidemic of 1977 in India, the importance of PKDL as a potential...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics